Pharmacometabolomics of Statin Response by Krauss Ronald M, Zhu Hongjie, Kaddurah-Daouk Rima in Clinical pharmacology and therapeutics (2013). PubMed

Abstract

Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma LDL concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 14 August 2013 doi:10.1038/clpt.2013.164.

[ hide abstract ]

Discussed In Paper